Another study performed on colon cancer has demonstrated that GPR109A, the receptor for short-chain fatty acids, functions as a tumor inhibitor in CRC, and the IFNγ can be used to activate GPR109A transcription silenced by DNA methylation. Here, IFNG is linked to neoplasm.